📬 GI Cancer Intelligence Digest — Week 2026-W42

FDA approved adjuvant atezolizumab plus chemotherapy for stage III dMMR colon cancer on ATOMIC (3-year DFS 86.3% vs 76.2%, HR 0.50), MATTERHORN final OS was published in the Lancet, and RAS-targeted therapy in pancreatic cancer dominated the week's commentary.

⚡ TL;DR

📄 Publications

Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More. — Pancreatic ductal adenocarcinoma has long been regarded as a therapeutic 'drug graveyard', with modest gains from cytotoxic chemotherapy and numerous failed novel agents

🐦 Twitter / 🦋 Bluesky

RAS-targeted therapy in pancreatic cancer: a new Clinical Cancer Research commentary sets a second-line rule for daraxonrasib and pushes NGS to diagnosis — The commentary argues germline testing and tumor NGS should be performed at diagnosis in advanced PDAC, and that daraxonrasib should be the preferred second-line treatment for RAS G12-mutant disease with ECOG 0-1 after first-line chemotherapy
RAS inhibitors as pancreatic cancer prevention: a Science report raises small-molecule interception — A new Science report prompted clinicians to ask whether pancreatic cancer could be 'prevented' with small-molecule RAS inhibitors
Update: MATTERHORN final OS and EFS in print in the Lancet, and the conversation moves to the PD-L1-negative and diffuse-histology grey zones — Among 948 randomized patients, perioperative durvalumab plus FLOT reduced the risk of death by 22% versus placebo (HR 0.78; 95% CI 0.63-0.96; p=0.021)
Update: the ASTRO26 randomized trial of RFA versus SBRT for solitary HCC ≤2 cm keeps drawing radiation oncology scrutiny over its small size and wide confidence interval — 93 patients with solitary HCC ≤2 cm, all suitable for either treatment, were randomized to RFA versus SBRT 50 Gy in 5 fractions
FDA approves adjuvant atezolizumab plus chemotherapy for stage III dMMR colon cancer on ATOMIC, and clinicians immediately ask whether the chemotherapy is still needed — FDA approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of adult and pediatric patients 2 years of age and older with stage III dMMR colon cancer

Full details below ↓

📄 What's Being Published

Manuscripts:

Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More. — Yu Peter Y et al., Clin Cancer Res

Pancreatic ductal adenocarcinoma has long been regarded as a therapeutic "drug graveyard," with modest gains from cytotoxic combination chemotherapy and numerous failed novel agents. Direct RAS targeting has moved from concept to reality with the FDA approval of daraxonrasib (Rasonque) for adults with metastatic PDAC who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The commentary focuses on RAS-targeted therapies that have reached phase 3 trials and states that the current generation of trials will determine whether these strategies translate into durable survival gains.

Clinical bottom line: In advanced PDAC, the practical change today is to perform germline testing and tumor NGS at diagnosis so that RAS-mutant patients can access daraxonrasib and the phase 3 RAS-targeted trials now enrolling.

Read full article →

🔗 Also discussed on social media →

The early-onset pancreatic cancer paradox: a systematic review and meta-analysis. — Ruze Rexiati et al., J Natl Cancer Inst

Forty-eight studies from 15 countries, encompassing 1,659,432 patients (non-overlapping estimate: 695,936), compared early-onset with average-onset pancreatic cancer. Early-onset patients had a lower prevalence of diabetes (OR 0.39; 95% CI 0.21 to 0.72), more stage IV disease (OR 1.18; 95% CI 1.02 to 1.36), and higher chemotherapy utilization (OR 2.04; 95% CI 1.69 to 2.45; P < .001). Overall survival was comparable (HR 1.03; 95% CI 0.86 to 1.23; P = .76), and GRADE certainty was very low for all outcomes.

Clinical bottom line: Younger patients present at a more advanced stage but achieve the same survival when treated aggressively, so age alone should not temper multimodal therapy, and germline testing belongs in every patient diagnosed before 50 — though the very low certainty makes this guidance, not proof.

Read full article →

REVERCE II: a phase II trial of regorafenib followed by anti-EGFR therapy versus reverse sequencing in refractory metastatic colorectal cancer. — Abidoye Oluseyi B et al., Oncologist

This randomized phase II trial in RAS wild-type mCRC enrolled 22 patients (R-E: n = 12; E-R: n = 10) before premature closure. Median OS was 21.9 months with regorafenib first versus 13.3 months with anti-EGFR first (one-sided P = .114), while PFS1 was 2.5 vs 5.6 months (one-sided P = .998) and ORR for initial treatment was 0% vs 20% (2/8). No significant differences in adverse effects were observed between arms.

Clinical bottom line: With only 22 patients and early closure, REVERCE II does not change refractory mCRC practice, but the numerical overall survival advantage for regorafenib before anti-EGFR therapy keeps the sequencing question open for a properly powered trial.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

RAS-targeted therapy in pancreatic cancer: a new Clinical Cancer Research commentary sets a second-line rule for daraxonrasib and pushes NGS to diagnosis

The Clinical Cancer Research commentary by Peter Yu, Oberstein and Hidalgo recommends germline testing and tumor NGS at diagnosis in advanced PDAC, with daraxonrasib as the preferred second-line treatment for RAS G12-mutant disease with ECOG 0–1 after first-line chemotherapy; the FDA indication also allows use without prior systemic therapy in patients unfit for multiagent regimens. Response, however, varied sharply by KRAS allele, with the weakest subtype responding less often than to chemotherapy. Open questions include whether RAS inhibitors should replace or be combined with first-line chemotherapy, whether G12D-selective agents outperform multi-selective inhibition, and whether RAS inhibitors can be sequenced after resistance — while clinicians stressed it is not a cure. The debate is whether second-line daraxonrasib should be offered uniformly across G12 alleles or restricted by allele.

Key numbers: Overall ORR 33% · G12V ORR 50% · G12D ORR 24% · G12R ORR 7% vs 14% with chemotherapy

Discussed by: @dr_yakupergun, @pashtoonkasi, @DrMarkLythgoe, @OncoAlert, @EricTopol, @DrChoueiri

→ View representative tweet

Sources cited: Targeting RAS in pancreatic cancer (Cancer, 2026) · Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More. (Clin Cancer Res) · Cell Press

RAS inhibitors as pancreatic cancer prevention: a Science report raises small-molecule interception

A new Science report prompted clinicians to ask whether pancreatic cancer could be "prevented" with small-molecule RAS inhibitors, framed as part of the march against "undruggable" cancer genes, with MYC floated as the next target. Separately, integrated screens identified IMPDH2 as a target where guanine nucleotide depletion irreversibly inhibits pancreatic cancer growth and strengthens KRAS blockade. The trade-off is whether RAS-inhibitor chemoprevention is realistic for high-risk cysts or germline carriers, or whether toxicity and cost confine these agents to established cancer.

Discussed by: @DrChoueiri, @EricTopol

→ View representative tweet

Sources cited: AAAS Journals · Cell Press · MYC targeting by OMO-103 in solid tumors: a phase 1 trial (Nature Medicine, 2024)

Update: MATTERHORN final OS and EFS in print in the Lancet, and the conversation moves to the PD-L1-negative and diffuse-histology grey zones

Final results of the global, double-blind, placebo-controlled phase 3 MATTERHORN trial (Janjigian YY et al., Lancet) show perioperative durvalumab plus FLOT improved pathological response, EFS and overall survival with no major unexpected safety signal, establishing a new perioperative standard option. Clinicians noted no clear basis to exclude durvalumab for PD-L1 TAP <1%, called the diffuse-histology result hypothesis-generating rather than proof of no benefit, and observed that the OS benefit persisted after excluding MSI-H disease. pCR was strongly prognostic but offers no evidence yet for de-escalation, and the practice-changing result comes from the overall population — leaving open whether PD-L1-negative and diffuse-type patients should receive durvalumab.

Key numbers: OS HR 0.78 (95% CI 0.63–0.96; p=0.021) · Risk of death reduced 22% vs placebo · Diffuse histology HR 0.98

Discussed by: @ChandrakanthMv, @ChandrakanthMv, @DraMartinezLago, @OncoAlert

→ View representative tweet

Sources cited: Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for re… (The Lancet, 2026)

Update: the ASTRO26 randomized trial of RFA versus SBRT for solitary HCC ≤2 cm keeps drawing radiation oncology scrutiny over its small size and wide confidence interval

Wang et al. randomized 93 patients with solitary HCC ≤2 cm, all suitable for either treatment, to RFA versus SBRT 50 Gy/5 fx; SBRT met noninferiority for local control, with similar survival and acute toxicity. The commentator cautioned against overinterpreting a small, single-center interim trial with a wide CI, yet called it another randomized data point supporting SBRT as a legitimate definitive ablative option rather than a fallback, while others noted TARE can also deliver ablative RT and that NRG-GI003 showed dosimetric but no clinical benefit with protons. The debate is whether SBRT should be a first-choice option or RFA should remain the default outside protocol.

Key numbers: 2-yr LPFS 87.0% (RFA) vs 91.5% (SBRT) · Difference +4.5%, meeting noninferiority · 2-yr OS ~98% in both arms

Discussed by: @jryckman3, @NiuSanford, @OncoAlert

→ View representative tweet

FDA approves adjuvant atezolizumab plus chemotherapy for stage III dMMR colon cancer on ATOMIC, and clinicians immediately ask whether the chemotherapy is still needed

The FDA approved atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant treatment for adult and pediatric patients 2 years and older with stage III dMMR colon cancer (dMMR: 10-15% of stage III cases), with subcutaneous Tecentriq Hybreza approved too; disease-free survival improved substantially, but OS is not mature. Clinicians flagged more grade 4 neutropenia with atezolizumab and asked how much the chemotherapy contributes in light of NICHE-2, with the next step framed as whether IO alone without chemotherapy can be used. Others asked whether dMMR testing should be upfront in all non-emergent resectable colon cancers, so patients could be identified for neoadjuvant immunotherapy instead.

Key numbers: 3-yr DFS 86.3% vs 76.2%, HR 0.50 (95% CI 0.35–0.73) · Grade 3–4 AEs 84.1% vs 71.9%

Discussed by: @OncBrothers, @ilyassahinMD, @ilyassahinMD, @FlavioRochaMD, @DrAllanPereira, @EladSharonMD, @ozdogan_md, @ChandrakanthMv

→ View representative tweet

Sources cited: FDA press release · Targeted Oncology

ctDNA NGS in advanced biliary tract cancer: 10,937 patients show better feasibility, faster turnaround and strong prognostic separation

In 10,937 patients, ctDNA NGS was more often feasible than tissue testing, returned results faster, showed high ESCAT-I concordance, and ctDNA detection separated survival, supporting the view that ctDNA can expand access and accelerate precision medicine. A separate international collaborative study in J Hepatology associated matched targeted therapy after first-line chemoimmunotherapy with longer overall survival in second line. The question is whether ctDNA NGS should replace tissue as the first molecular test in advanced biliary tract cancer.

Key numbers: Feasibility 90% vs 50% tissue · TAT 8 vs 27 days · ESCAT-I concordance 83% · mOS 27.7 vs 13.6 mo by ctDNA

Discussed by: @ArndtVogel, @hongjaechon, @hongjaechon, @LorenzaRimassa

→ View representative tweet

Sources cited: AACR Journals · Elsevier

JAMA Surgery: chemotherapy plus gastrectomy beats either alone in gastric cancer with positive peritoneal cytology or localized peritoneal metastasis

In gastric cancer with positive peritoneal lavage cytology or localized peritoneal metastasis, chemotherapy plus gastrectomy was associated with better survival than either gastrectomy or chemotherapy alone — an association, not a causal effect. Surgeons separately flagged underutilization of staging laparoscopy before neoadjuvant systemic therapy, and an update of the phase 3 NEO-CRAG trial at the 2026 ASTRO Annual Meeting reported the impact of pre-treatment staging laparoscopy on tumor control and survival comparisons. The debate is whether staging laparoscopy should be mandatory before neoadjuvant therapy so these patients are not mislabeled as unresectable.

Discussed by: @JAMASurgery, @AnnSurgOncol, @GiOncNow

→ View representative tweet

Sources cited: Treatment Outcomes for Gastric Cancer With Positive Peritoneal Lavage Cytology or Localiz… (JAMA Surgery, 2026)

GETNE SOUTH-NEC: perioperative chemotherapy and long-term cure in resected grade 3 gastroenteropancreatic neuroendocrine carcinomas

The GETNE SOUTH-NEC study examined perioperative chemotherapy and long-term cure in resected grade 3 gastroenteropancreatic neuroendocrine carcinomas. Clinicians also noted that grade 3 NETs raise real dosing questions with cabozantinib. The open question is whether perioperative chemotherapy should be offered to every patient with resected grade 3 neuroendocrine carcinoma in pursuit of long-term cure.

Discussed by: @UGrewalMD, @hongjaechon, @OncLive

→ View representative tweet

Sources cited: European Journal of Cancer · Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative,… (International Journal of Cancer, 2026) · OncLive

Daraxonrasib plus zoldonrasib enters phase 3 in first-line KRAS G12D metastatic pancreatic cancer, and Incyte's zecdarasib starts its own phase 3

Dosing has begun in the global phase 3 RASolute 309 trial of daraxonrasib (RAS(ON) multi-selective) plus zoldonrasib (RAS(ON) G12D-selective) versus gemcitabine plus nab-paclitaxel in first-line metastatic RAS G12D PDAC. Incyte's non-covalent KRAS G12D inhibitor zecdarasib (INCB161734) has begun its own phase 3 trial in combination with chemotherapy, after Brandon Huffman of Dana-Farber called its 37% ORR in the heavily pretreated DAWN-303 population, often in third line, quite significant. For treatment-naive KRAS G12D disease, the question is whether a chemotherapy-free doublet or a G12D inhibitor added to chemotherapy is the right first-line strategy.

Discussed by: @phsiao4, @phsiao4, @pashtoonkasi

→ View representative tweet

Sources cited: A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in… (Science, 2025) · Targeted Oncology · OncLive

🔥 Top Ranked Tweets

Gil Morgan, MD @weoncologists

RT @OncoAlert: Is perioperative immunotherapy finally changing the standard of care in resectable gastric cancer? 🧬

https://t.co/EsjmQuAX7F

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma MATTERHORN🗻 : final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

The phase 3 MATTERHORN trial found that adding perioperative durvalumab to FLOT chemotherapy🧪 significantly improved overall survival in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
➡️ Among 948 randomized patients, durvalumab reduced the risk of death by 22% compared with placebo (HR 0.78; 95% CI 0.63–0.96; p=0.021).
✅️ These results support perioperative durvalumab plus FLOT as a new standard treatment option, with no major unexpected safety signal identified.

@YJanjigianMD, @salahAlBatran, @WainbergZev, @moisheliberman, @LizzySmyth1, @TaberneroJosep

@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @AndresC27622123, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara, @GaiaGriguolo, @scocmem

🔖 9 ❤️ 31 🔁 13 👁 4,411

📬 GI Cancer Intelligence Digest — Week 2026-W42

⚡ TL;DR

📄 What's Being Published

🗣️ What People Were Discussing This Week

RAS-targeted therapy in pancreatic cancer: a new Clinical Cancer Research commentary sets a second-line rule for daraxonrasib and pushes NGS to diagnosis

RAS inhibitors as pancreatic cancer prevention: a Science report raises small-molecule interception

Update: MATTERHORN final OS and EFS in print in the Lancet, and the conversation moves to the PD-L1-negative and diffuse-histology grey zones

Update: the ASTRO26 randomized trial of RFA versus SBRT for solitary HCC ≤2 cm keeps drawing radiation oncology scrutiny over its small size and wide confidence interval

FDA approves adjuvant atezolizumab plus chemotherapy for stage III dMMR colon cancer on ATOMIC, and clinicians immediately ask whether the chemotherapy is still needed

ctDNA NGS in advanced biliary tract cancer: 10,937 patients show better feasibility, faster turnaround and strong prognostic separation

JAMA Surgery: chemotherapy plus gastrectomy beats either alone in gastric cancer with positive peritoneal cytology or localized peritoneal metastasis

GETNE SOUTH-NEC: perioperative chemotherapy and long-term cure in resected grade 3 gastroenteropancreatic neuroendocrine carcinomas

Daraxonrasib plus zoldonrasib enters phase 3 in first-line KRAS G12D metastatic pancreatic cancer, and Incyte's zecdarasib starts its own phase 3

🔥 Top Ranked Tweets

🧪 Newly Recruiting Trials